RBC Europe’s Ligand Pharmaceuticals LGND Stock Holding History

RBC Europe’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-112	Closed	-$11K	–	649
2021 Q4	$11K	Hold	112	–	–	﹤0.01%	519
2021 Q3	$9.75K	Hold	112	–	–	﹤0.01%	940
2021 Q2	$9.18K	Hold	112	–	–	﹤0.01%	973
2021 Q1	$10.7K	Sell	112 -181	-62%	-$17.1K	﹤0.01%	899
2020 Q4	$18.2K	Hold	293	–	–	﹤0.01%	744
2020 Q3	$17.4K	Hold	293	–	–	﹤0.01%	671
2020 Q2	$20.5K	Sell	293 -281	-49%	-$17.8K	﹤0.01%	625
2020 Q1	$26K	Hold	574	–	–	﹤0.01%	508
2019 Q4	$37.3K	Hold	574	–	–	﹤0.01%	520
2019 Q3	$35.6K	Buy	574 +281	+96%	+$17.6K	﹤0.01%	510
2019 Q2	$20.9K	Hold	293	–	–	﹤0.01%	645
2019 Q1	$23K	Hold	293	–	–	﹤0.01%	623
2018 Q4	$24.8K	Hold	293	–	–	﹤0.01%	591
2018 Q3	$50.2K	Hold	293	–	–	0.01%	476
2018 Q2	$37.9K	Sell	293 -2	-0.7%	-$223	﹤0.01%	529
2018 Q1	$30.4K	Hold	295	–	–	﹤0.01%	582
2017 Q4	$25.2K	Hold	295	–	–	﹤0.01%	626
2017 Q3	$25.1K	Buy	+295	New	+$23.4K	﹤0.01%	635

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

RBC Europe's LGND Position: Q1 2022 in Review

RBC Europe sold out of Ligand Pharmaceuticals (LGND) in Q1 2022, closing a stake of 112 shares — an estimated $11K sold.

RBC Europe first reported a position in LGND in Q3 2017 and held it in 18 quarters. The position peaked at $50.2K in Q3 2018. 208 funds tracked by Wall St. Rank hold LGND as of Q1 2022.

RBC Europe reported no remaining Ligand Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
RBC Europe sold 112 Ligand Pharmaceuticals shares in Q1 2022, an estimated $11K.
RBC Europe first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 18 quarters.
RBC Europe's Ligand Pharmaceuticals position peaked at $50.2K in Q3 2018.
208 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2022.

Based on RBC Europe's 13F filing for Q1 2022, filed 14 Nov 2022.